Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Riederer

Showing results (511-520 of 587) with videos related to

Pageof 59
Sort By:
Journal of Neural Transmission. Supplementum|November 7, 2007
Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitusI Tahirovic, E Sofic, A Sapcanin, et al.
Pharmacopsychiatry|October 9, 2014
SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcomeF Proft, J Kopf, D Olmes, et al.
Neuroscience Letters|March 14, 1994
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's diseaseB Janetzky, S Hauck, M B Youdim, et al.
The American Journal of Psychiatry|June 9, 1999
Persistence of haloperidol in human brain tissueJ Kornhuber, A Schultz, J Wiltfang, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 19, 2015
Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγS Strobel, E Grünblatt, P Riederer, et al.
Pharmacopsychiatry|March 5, 2015
SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcomeF Proft, J Kopf, D Olmes, et al.
Life Sciences|January 1, 1996
Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's diseaseJ Thome, G Münch, R Müller, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 22, 2001
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegilineA Kupsch, J Sautter, M E Götz, et al.
Neuroscience Letters|May 2, 2002
Unaltered brain levels of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal in Alzheimer's diseaseM E Götz, M Wacker, C Luckhaus, et al.
Pharmacopsychiatry|November 1, 1988
The new generation of selective monoamine oxidase-inhibitors: biochemical, pharmacological and clinical perspectivesP Riederer, G Laux, H Beckmann, et al.
Pageof 59

Showing results (511-520 of 587) with videos related to

Sort By:
Pageof 59
Journal of Neural Transmission. Supplementum|November 7, 2007
Brain antioxidant capacity in rat models of betacytotoxic-induced experimental sporadic Alzheimer's disease and diabetes mellitusI Tahirovic, E Sofic, A Sapcanin, et al.
Pharmacopsychiatry|October 9, 2014
SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcomeF Proft, J Kopf, D Olmes, et al.
Neuroscience Letters|March 14, 1994
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's diseaseB Janetzky, S Hauck, M B Youdim, et al.
The American Journal of Psychiatry|June 9, 1999
Persistence of haloperidol in human brain tissueJ Kornhuber, A Schultz, J Wiltfang, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|January 19, 2015
Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer's disease progression: CX3CL1, TREM2, and PPARγS Strobel, E Grünblatt, P Riederer, et al.
Pharmacopsychiatry|March 5, 2015
SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcomeF Proft, J Kopf, D Olmes, et al.
Life Sciences|January 1, 1996
Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer's diseaseJ Thome, G Münch, R Müller, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 22, 2001
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegilineA Kupsch, J Sautter, M E Götz, et al.
Neuroscience Letters|May 2, 2002
Unaltered brain levels of 1,N2-propanodeoxyguanosine adducts of trans-4-hydroxy-2-nonenal in Alzheimer's diseaseM E Götz, M Wacker, C Luckhaus, et al.
Pharmacopsychiatry|November 1, 1988
The new generation of selective monoamine oxidase-inhibitors: biochemical, pharmacological and clinical perspectivesP Riederer, G Laux, H Beckmann, et al.
Pageof 59